ArticleNutrition journal2025
Correlation of nutritional support and immunonutritional indicators with prognosis and survival in esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.
Article in Nutrition journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Influencing factors of cognitive frailty in older patients with esophageal cancer undergoing chemotherapy: a mixed-methods study.Frontiers in oncology · 2026Article
- Interpretable survival modeling integrating nutritional-inflammatory biomarkers in elderly patients with locally advanced esophageal squamous cell carcinoma treated with definitive radiotherapy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsEsophageal squamous cell carcinoma (ESCC) is commonly associated with high rates of malnutrition, adversely affecting patient outcomes. This study aims to assess the impact of nutritional support combined with concurrent chemoradiotherapy (CCRT) on survival and prognosis in ESCC patients, utilizing prognostic models based on five key immunonutritional indicators.
methodsIn this retrospective study, we reviewed the medical records of 200 esophageal squamous cell carcinoma patients who were treated between January 2017 and June 2022. Patients were categorized into two groups based on their treatment records: one group received nutritional support in addition to standard CCRT, and the other received only CCRT. We retrospectively analyzed survival outcomes using Kaplan-Meier curves and log-rank tests, and identified independent prognostic factors through Cox proportional hazards models. The study further assessed five specific immunonutritional indicators to develop and validate predictive nomogram models. The effectiveness of these models was evaluated using receiver operating characteristic (ROC) curve analysis to determine their predictive accuracy for patient outcomes.
resultsNutritional support improved overall survival (OS) and progression-free survival (PFS) compared to the non-nutritional group. Patients in the nutritional group showed better biochemical markers and quality of life with fewer treatment-related complications. The nomogram models based on the immunonutritional indicators demonstrated strong predictive accuracy for both OS and PFS, with LMY and PAR showing the highest prognostic power.
conclusionsIntegrating nutritional support into the treatment plan for ESCC patients undergoing CCRT enhances may enhance treatment tolerance, reduce toxicity, and indirectly contribute to improved survival rates, quality of life, and fewer complications. The five immunonutritional indicators provide robust predictive capabilities for patient outcomes, supporting the use of personalized nutritional interventions and nomogram models in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.